Your browser doesn't support javascript.
loading
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.
Padrón, Lacey J; Maurer, Deena M; O'Hara, Mark H; O'Reilly, Eileen M; Wolff, Robert A; Wainberg, Zev A; Ko, Andrew H; Fisher, George; Rahma, Osama; Lyman, Jaclyn P; Cabanski, Christopher R; Yu, Jia Xin; Pfeiffer, Shannon M; Spasic, Marko; Xu, Jingying; Gherardini, Pier Federico; Karakunnel, Joyson; Mick, Rosemarie; Alanio, Cécile; Byrne, Katelyn T; Hollmann, Travis J; Moore, Jonni S; Jones, Derek D; Tognetti, Marco; Chen, Richard O; Yang, Xiaodong; Salvador, Lisa; Wherry, E John; Dugan, Ute; O'Donnell-Tormey, Jill; Butterfield, Lisa H; Hubbard-Lucey, Vanessa M; Ibrahim, Ramy; Fairchild, Justin; Bucktrout, Samantha; LaVallee, Theresa M; Vonderheide, Robert H.
Afiliación
  • Padrón LJ; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. lpadron@parkerici.org.
  • Maurer DM; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • O'Hara MH; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.
  • O'Reilly EM; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Wolff RA; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wainberg ZA; University of California, Los Angeles, Los Angeles, CA, USA.
  • Ko AH; University of California, San Francisco, San Francisco, CA, USA.
  • Fisher G; Stanford University, Stanford, CA, USA.
  • Rahma O; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Lyman JP; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Cabanski CR; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Yu JX; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Pfeiffer SM; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Spasic M; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Xu J; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Gherardini PF; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Karakunnel J; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Mick R; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.
  • Alanio C; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.
  • Byrne KT; Parker Institute of Cancer Immunotherapy at the University of Pennsylvania, Philadelphia, PA, USA.
  • Hollmann TJ; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
  • Moore JS; Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
  • Jones DD; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.
  • Tognetti M; Parker Institute of Cancer Immunotherapy at the University of Pennsylvania, Philadelphia, PA, USA.
  • Chen RO; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Yang X; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.
  • Salvador L; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.
  • Wherry EJ; Biognosys AG, Schlieren, Switzerland.
  • Dugan U; Personalis, Inc., Menlo Park, CA, USA.
  • O'Donnell-Tormey J; Apexigen, Inc., San Carlos, CA, USA.
  • Butterfield LH; Bristol Myers Squibb, New York, NY, USA.
  • Hubbard-Lucey VM; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.
  • Ibrahim R; Parker Institute of Cancer Immunotherapy at the University of Pennsylvania, Philadelphia, PA, USA.
  • Fairchild J; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
  • Bucktrout S; Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
  • LaVallee TM; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Vonderheide RH; Cancer Research Institute, New York, NY, USA.
Nat Med ; 28(6): 1167-1177, 2022 06.
Article en En | MEDLINE | ID: mdl-35662283
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Ductal Pancreático Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Ductal Pancreático Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos